| Citation: |
DENG Kangli, CUI Diansheng, LUO Bo, JIA Quan'an, LIU Sanhe, HUANG Lei, ZHU Hui, WEI Shaozhong. Efficacy of Definitive External-beam Radiotherapy Versus Radical Prostatectomy on Clinically Localized High-risk Prostate Cancer Patients: A Retrospective Study[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1113-1117. DOI: 10.3971/j.issn.1000-8578.2019.19.0965
|
To retrospectively compare the efficacy between definitive external-beam radiotherapy (ExRT) and radical prostatectomy(RP) on patients with localized high-risk prostate cancer (PCa).
We retrospectively studied 150 patients with high-risk PCa(T2b-T4N0M0) who underwent definitive ExRT or RP. The inclusion criteria for high-risk PCa were PSA≥20 ng/ml or above cT3 or GS≥8. The primary end point was biochemical failure free survival(BFFS), and the secondary end point was distant metastasis free survival(DMFS), cancer-specific survival(CSS) and overall survival(OS).
A total of 88 patients underwent definitive ExRT and androgen deprivation therapy(ADT), and the remaining 62 patients underwent RP and pelvic lymphadenectomy(PLND). The median age and follow-up time were statistically significant between ExRT and RP groups(P < 0.05). The biochemical failure(BF) rate in ExRT group was significantly lower than that in RP group(P < 0.001), while BFFS was significantly increased(P < 0.001). The DMFS, CSS and OS were not significantly different between the two groups.
BF rate after definitive ExRT in patients with localized high-risk PCa are significantly lower than those undergoing RP, while BFFS is significantly increased.
| [1] |
Weiner AB, Matulewicz RS, Schaeffer EM, et al. Contemporary management of men with high-risk localized prostate cancer in the United States[J]. Prostate Cancer Prostatic Dis, 2017, 20(3): 283-288. doi: 10.1038/pcan.2017.5
|
| [2] |
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol, 2017, 71(4): 618-629. doi: 10.1016/j.eururo.2016.08.003
|
| [3] |
Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase Ⅲ trial of the duration of elective androgen deprivation in locally advanced prostate cancer[J]. J Clin Oncol, 2008, 26(15): 2497-2504. doi: 10.1200/JCO.2007.14.9021
|
| [4] |
Johnstone PA, Ward KC, Goodman M, et al. Radical prostatectomy for clinical T4 prostate cancer[J]. Cancer, 2006, 106(12): 2603-2609. doi: 10.1002/cncr.21926
|
| [5] |
Siddiqui SA, Boorjian SA, Blute ML, et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer[J]. BJU Int, 2011, 107(3): 383-388. doi: 10.1111/j.1464-410X.2010.09565.x
|
| [6] |
Spahn M, Weiss C, Bader P, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation[J]. Urol Int, 2010, 84(2): 164-173. doi: 10.1159/000277593
|
| [7] |
Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. PartⅠ: risk stratification, shared decision making, and care options[J]. J Urol, 2018, 199(3): 683-690. doi: 10.1016/j.juro.2017.11.095
|
| [8] |
Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study[J]. J Natl Cancer Inst, 2004, 96(18): 1358-1367. doi: 10.1093/jnci/djh259
|
| [9] |
Sundi D, Tosoian JJ, Nyame YA, et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers[J]. Cancer, 2019, 125(3): 391-397. doi: 10.1002/cncr.31833
|
| [10] |
Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome[J]. BJU Int, 2005, 95(6): 751-756. doi: 10.1111/j.1464-410X.2005.05394.x
|
| [11] |
Zwergel U, Suttmann H, Schroeder T, et al. Outcome of prostate cancer patients with initial PSA > or =20 ng/ml undergoing radical prostatectomy[J]. Eur Urol, 2007, 52(4): 1058-1065. doi: 10.1016/j.eururo.2007.03.056
|
| [12] |
Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2005, 366(9485): 572-578. doi: 10.1016/S0140-6736(05)67101-2
|
| [13] |
Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)[J]. Lancet, 2012, 380(9858): 2018-2027. doi: 10.1016/S0140-6736(12)61253-7
|
| [14] |
Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer[J]. Cancer, 2011, 117(13): 2883-2891. doi: 10.1002/cncr.25900
|
| [15] |
Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline[J]. J Urol, 2013, 190(2): 441-449. doi: 10.1016/j.juro.2013.05.032
|
| [16] |
Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer[J]. Eur Urol, 2009, 55(6): 1251-1265. doi: 10.1016/j.eururo.2009.03.012
|
| [17] |
Briganti A, Joniau S, Gontero P, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer[J]. Eur Urol, 2012, 61(3): 584-592. doi: 10.1016/j.eururo.2011.11.043
|
| [18] |
Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer--therapeutic?[J]. J Urol, 2008, 179(2): 408-413. doi: 10.1016/j.juro.2007.09.027
|
| [19] |
Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5): 1310-1317. doi: 10.1016/j.ijrobp.2010.01.006
|
| [20] |
Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09[J]. J Clin Oncol, 2010, 28(7): 1106-1111. doi: 10.1200/JCO.2009.25.8475
|
| [21] |
Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix[J]. J Clin Oncol, 2010, 28(9): 1508-1513. doi: 10.1200/JCO.2009.22.2265
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: